Clinical Study

Natural History And Bio-Specimen Repository For Dystonia

Posted Date: Aug 8, 2014

  • Investigator: Alberto Espay
  • Co-Investigator: Catherine Krier
  • Specialties: Parkinson's Disease, Neurology, Movement Disorders
  • Type of Study: Observational/Survey

This research study is being done to create a repository collection used for future research on dystonia and other diseases. The repository will store bio specimens, videos, and clinical information. Bio-specimens include things like blood, DNA, and cell lines from your body. University of Cincinnati and other research centers will work together to put in information, videos, and samples from about ten thousand adults. These adults include people who have dystonia or related disorders. Researchers around the world will be able to use information, videos, and samples from all participants to do research that may lead to new tests and treatments. Your videos may be used to create teaching programs that will help medical professionals administer neurological exams or use specific rating scales.If your dystonia is secondary to taking medications or to another disorder, you will not be able to participate in this study.Also for you to participate it it must be at least 2 months since your last botulinum toxin injection or your injections could have taken place earlier on the same day as your study visit. Being in a research study does not take the place of routine physical exams or visits to your own doctor. You should not rely on this study to diagnose or treat medical problems.

Criteria:

You Have Been Asked To Take Part In This Study Because You Are At Least 18 Years Of Age And Have Dystonia Or A Related Disorder.

Keywords:

Involuntary Muscle Contractions, Parkinson's Disease, Espay, Dystonia, Null

For More Information:

Katie Krier
(513) 558-0169
katie.krier@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.